New DAAs and New DDIs: How Drug-Drug Interactions Continue To Vex HCV Treatment
Charles W. Flexner, MD
Professor of Medicine, Pharmacology and Molecular Sciences, and International Health
Johns Hopkins University School of Medicine, Baltimore, MD
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2016. All rights reserved.
Charles Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His current research includes the discovery and development of new molecules and formulations for long-acting parenteral administration for treatment and prevention of HIV infection. Dr. Flexner is the Deputy Director of the Institute for Clinical and Translational Research at Johns Hopkins, and Co-Principal Investigator of the Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit. He currently serves as a consultant to the Bill and Melinda Gates Foundation and the Clinton Health Access Initiative, and served as a consultant on FDA reform to the United States House of Representatives.
At the completion of this educational session, learners will:
- Understand the potential for clinically significant drug-drug interactions involving the most recently approved HCV direct acting agents.
- Appreciate differences in the drug interaction potential of ledipasivir and velpatasvir.
- Know readily available resources for managing and avoiding HCV DAA drug interactions.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
You must be logged in to post a comment. Login | Register
